Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Timbetasin - RegeneRx Biopharmaceuticals

Drug Profile

Timbetasin - RegeneRx Biopharmaceuticals

Alternative Names: Fx peptide; GBT-201; RGN-137; RGN-259; RGN-352; RGN-457; TB4; TB4 16-38; Thymosin B4; Thymosin beta 4-16-38; Thymosin beta-4; Thymosin-beta-4-RegeneRx-Biopharmaceuticals; Timbetasin-National-Institutes-of-Health-(USA)/RegeneRx-Biopharmaceuticals; Tβ4

Latest Information Update: 10 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Chonbuk National University; Defiante Farmaceutica; Lenus Therapeutics; RegeneRx Biopharmaceuticals; sigma-tau SpA; United States Army Medical Research Institute of Chemical Defense; Wayne State University; Zhejiang University
  • Class Anti-infectives; Anti-inflammatories; Anti-ischaemics; Antibronchitics; Antifibrotics; Eye disorder therapies; Foot disorder therapies; Heart failure therapies; Neuroprotectants; Peptide hormones; Proteins; Skin disorder therapies; Thymus hormones; Vascular disorder therapies
  • Mechanism of Action Actin modulators; Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants; Heat-shock protein modulators; MicroRNA modulators; Nerve growth factor stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis; Epidermolysis bullosa
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Dry eyes; Keratitis
  • Phase II Epidermolysis bullosa
  • Phase I Multiple sclerosis; Myocardial infarction
  • Preclinical Diabetic neuropathies; Septic shock; Stroke
  • No development reported Brain injuries; Burns; Eye disorders; Musculoskeletal disorders; Pressure ulcer; Pulmonary arterial hypertension; Varicose ulcer
  • Discontinued Alopecia; Bronchiectasis; Cystic fibrosis; Diabetic foot ulcer; Diabetic retinopathy

Most Recent Events

  • 30 Sep 2019 Adverse events data from a phase III ARISE-3 trial in Dry eye syndrome released by RegeneRx
  • 29 Jul 2019 Phase I development is ongoing in USA for Multiple sclerosis
  • 29 Jul 2019 Preclinical development is ongoing in USA for Stroke and Septic shock
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top